Luc Starmans

Vivalyx is dedicated to saving lives of people suffering from organ failure by increasing the vitality and number of donor organs.

At PL BioScience, we are experts in Human Platelet Lysate. Our mission is to support advances in cellular research and therapy with our revolutionary technology: the ELAREM™ HPL platform. Its xeno-free origin, combined with its naturally rich growth factor content not only supports cell growth and expansion, but also enables various applications. And with Research- and GMP-grade products available, ELAREM™ covers all steps of cell expansion in academic research, pre-clinical research and cellular therapy. This ensures seamless transitions in regenerative medicine – from blood bank, to bench, to bedside. Our story goes back to 2015, with the mission to deliver xeno-free cell culture supplements. Today, we continue to change the possibilities of cell expansion; researchers switch from Fetal Bovine Serum to our animal suffering-free products. Our signature innovation continues to guide us, as we work to support all stages of research, with premium quality HPL. Join us today in Innovating Cell Culture!

At niostem (formerly Mane Biotech), we aim to develop innovative technologies that unlock the body’s regenerative potential, empowering our customers to live healthier lives. Our first use case is common hair loss/pattern baldness. Our smart wearable device (nio1) stops hair loss in 3 months and supports hair regrowth from 6 months.

Hy2Care® is a spin-off company of the MIRA Institute of the University Twente, the Netherlands, one of the world’s leading institutes in biomedical and chemical engineering. Since 2007 more than 4 million EURO has been invested in developing a platform technology. We filed three patents in Europe and US and additional filing of IP is ongoing. Product prototyping and first animal testing have been completed. Our market study and face-to-face interviews with key opinion leaders confirm the strong interest of orthopedic surgeons with recognized international reputation to implement our products in their day-to-day practice

Vivalyx is dedicated to saving lives of people suffering from organ failure by increasing the vitality and number of donor organs.

Brightlands Venture Partners (BVP) is a venture capital fund manager backing founders who turn breakthrough solutions into lasting impact. We invest in early-stage companies addressing complex, system-level challenges across health, agrifood, and renewable chemistry; sectors that are fundamental to a resilient, future-proof society. We believe the transition toward healthier and more sustainable systems is both a structural necessity and one of the most compelling long-term investment opportunities of our generation. We partner with founders and teams who combine deep domain expertise, strong execution capability, and clear growth ambition. With our current fund, we invest at the Seed to Series A stage, with initial ticket sizes ranging from €250k to €2m, focusing on companies based in Europe. Impact has shaped our investment approach from the very beginning. Long before impact investing became a label, it was part of our DNA. Today, this conviction is embedded across our full investment lifecycle, in line with our SFDR Article 9 classification. We can act as lead investor or co-investor and consistently reserve capital for follow-on rounds, ensuring long-term alignment with our portfolio companies. BVP currently manages four funds with €120 million in committed capital. 📍 Our team is based in the Netherlands, Luxembourg, and Switzerland, and we are active across Europe. 📩 For questions, pitches, or collaborations, email works best: info@bvp.capital

At PL BioScience, we are experts in Human Platelet Lysate. Our mission is to support advances in cellular research and therapy with our revolutionary technology: the ELAREM™ HPL platform. Its xeno-free origin, combined with its naturally rich growth factor content not only supports cell growth and expansion, but also enables various applications. And with Research- and GMP-grade products available, ELAREM™ covers all steps of cell expansion in academic research, pre-clinical research and cellular therapy. This ensures seamless transitions in regenerative medicine – from blood bank, to bench, to bedside. Our story goes back to 2015, with the mission to deliver xeno-free cell culture supplements. Today, we continue to change the possibilities of cell expansion; researchers switch from Fetal Bovine Serum to our animal suffering-free products. Our signature innovation continues to guide us, as we work to support all stages of research, with premium quality HPL. Join us today in Innovating Cell Culture!

At niostem (formerly Mane Biotech), we aim to develop innovative technologies that unlock the body’s regenerative potential, empowering our customers to live healthier lives. Our first use case is common hair loss/pattern baldness. Our smart wearable device (nio1) stops hair loss in 3 months and supports hair regrowth from 6 months.

Hy2Care® is a spin-off company of the MIRA Institute of the University Twente, the Netherlands, one of the world’s leading institutes in biomedical and chemical engineering. Since 2007 more than 4 million EURO has been invested in developing a platform technology. We filed three patents in Europe and US and additional filing of IP is ongoing. Product prototyping and first animal testing have been completed. Our market study and face-to-face interviews with key opinion leaders confirm the strong interest of orthopedic surgeons with recognized international reputation to implement our products in their day-to-day practice